Kata Szántó

Dr. Kata Szántó

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2017 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
KSKata Szántó
Kata Szántó
TMTamás Molnár
Tamás Molnár
KFKlaudia Farkas
Klaudia Farkas
Kata Szántó, Tamás Molnár, Klaudia Farkas; New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizu

6 December 2019 in Expert Opinion on Biological Therapy
Verified
Journal Article
Open access
RBRenáta Bor
Renáta Bor
AFAnna Fábián
Anna Fábián
MMMária Matuz
Mária Matuz
ZSZoltán Szepes
Zoltán Szepes
KFKlaudia Farkas
Klaudia Farkas
TMTamás Molnár
Tamás Molnár
Background: GEMINI trials demonstrated the therapeutic efficacy of vedolizumab (VDZ) in Crohn’s disease (CD) and ulcerative colitis (UC). Research design and methods: Aim of this study was to determine the real-life effectiveness of VDZ on endoscopic healing in the Hungarian nationwide cohort of inflammatory bowel disease (IBD) patients based on changes on clinical and endoscopic scores. Every adult IBD patient in the country (121 UC and 83 CD) who completed short-term VDZ therapy were enrolled, of which 72 UC and 52 CD patients could complete the long-term therapy. Results: Rates of endoscopic healing were substantially higher in UC compared with CD patients during short- and long-term therapy (52.9% vs. 21.7%, p<0.0001, and 51.4% vs. 21.2%, p=0.015, respectively). In CD, the rate of endoscopic healing was lower at week 14 compared with week 22 (14.5% vs. 37.0%, p=0.026). Prior anti-TNF-alpha therapy (88.73%) was not associated with a significant decrease in therapeutic response. Average disease duration was significantly lower in CD patients achieving endoscopic healing at week 52 (11.75 vs. 5.27 years, p=0.007). Conclusions: VDZ therapy is an effective therapeutic option in anti-TNF-alpha refractory IBD. However, endoscopic healing rate was substantially lower and showed a significant delay in CD compared with UC.

1 January 2023 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PBPéter Bacsur 
Péter Bacsur 
MRMariann Rutka
Mariann Rutka
AAAndrás Asbóth
András Asbóth
TRTamás Resál
Tamás Resál
KSKata Szántó
Kata Szántó
TMTamás Molnár
Tamás Molnár
Background: In patients with inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), numerous cases of exacerbations could be observed after colonoscopy, raising the possible pathogenetic effect of colonic microbiota alterations in IBD flare. Objectives: We aimed to investigate the changes in the fecal microbiota composition in IBD patients influenced by the bowel preparation with sodium picosulfate. Design: We enrolled patients with IBD undergoing bowel preparation for colonoscopy in the prospective cohort study. The control group (Con) comprised non-IBD patients who underwent colonoscopy. Clinical data, blood, and stool samples were collected before colonoscopy (timepoint A), 3 days later (timepoint B), and 4 weeks later (timepoint C). Methods: Disease activity and gut microbiota changes were assessed at each timepoint. Fecal microbiota structure – at family level – was determined by sequencing the V4 region of the 16S rRNA gene. Statistical analysis included differential abundance analysis and Mann–Whitney tests. Results: Forty-one patients (9 CD, 13 UC, and 19 Con) were included. After bowel preparation, alpha diversity was lower in the CD group than in the UC ( p = 0.01) and Con ( p = 0.02) groups at timepoint B. Alpha diversity was significantly higher in the UC group than in the CD and Con ( p = 0.03) groups at timepoint C. Beta diversity difference differed between the IBD and Con ( p = 0.001) groups. Based on the differential abundance analysis, the Clostridiales family was increased, whereas the Bifidobacteriaceae family was decreased in CD patients compared to the Con at timepoint B. Conclusions: Bowel preparation may change the fecal microbial composition in IBD patients, which may have a potential role in disease exacerbation after bowel cleansing.

1 January 2022 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PBPéter Bacsur 
Péter Bacsur 
MMMária Matuz
Mária Matuz
TRTamás Resál
Tamás Resál
PMPál Miheller
Pál Miheller
TSTamás Szamosi
Tamás Szamosi
KFKlaudia Farkas
Klaudia Farkas
Background: Treatment with antitumor necrosis factor alpha (anti-TNF-α) is safe and effective as first-line therapy; however, its efficacy is limited due to primary nonresponse (PNR) and secondary loss of response (LOR), resulting in treatment discontinuation in approximately 40%–50% of cases. Vedolizumab (VDZ) and ustekinumab (UST) therapies could be good alternatives in patient with anti-TNF failure; however, no head-to-head randomized comparison of these drugs as second- or third-line treatments has been made. Objectives: This study aimed to assess the treatment persistence and comparative effectiveness of UST and VDZ in patients with refractory Crohn’s disease (CD). Design: In this nationwide retrospective study, patients with CD on UST or VDZ maintenance therapy were enrolled. Clinical data at baseline, after induction, and at week 52 were obtained. Methods: Clinical and biochemical activities as well as corticosteroid-free remission (SFR) rates were assessed, while concomitant medications, comorbidities, hospitalizations, and surgeries were recorded during the follow-up to detect any predictors. Results: A total of 161 UST- and 65 VDZ-treated patients completed the follow-up. No significant difference in clinical or biochemical remission rates was observed after induction between the two treatment groups; however, clinical remission rate at week 52 was higher in UST group. UST showed superior drug persistence than VDZ (86.5%, 57.9%, p < 0.0001). The drug type was predictive of clinical SFR at week 52 [ p = 0.011, odds ratio (OR) = 2.39 with UST]. Drug failure rates were higher for VDZ than those for UST (PNR rates: 21.54% and 4.97%, respectively, p < 0.001, OR = 8.267, p = 0.001). LOR and escalations were more common during UST treatment (61.5% versus 36.9%, p < 0.001; 64.2% versus 23.1%, p < 0.001). Hospital and surgical admission rates did not differ significantly. Only one adverse event occurred with VDZ at week 20, which led to drug cessation. Conclusions: VDZ and UST were safe and effective for treating patients with CD in whom anti-TNF therapy failed. UST showed superior drug persistence than VDZ, but dose escalation was more frequent. Biologicals used in lower treatment lines resulted in better drug persistence.

26 September 2023 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
BJBoldizsár Jójárt
Boldizsár Jójárt
TRTamás Resál
Tamás Resál
DKDiana Kata
Diana Kata
TMTünde Molnár
Tünde Molnár
PBPéter Bacsur 
Péter Bacsur 
KFKlaudia Farkas
Klaudia Farkas
Background and Aims: Crohn’s disease [CD] and ulcerative colitis [UC] require lifelong treatment and patient monitoring. Current biomarkers have several limitations; therefore, there is an unmet need to identify novel biomarkers in inflammatory bowel disease [IBD]. Previously, the role of plasminogen activator inhibitor 1 [PAI-1] was established in the pathogenesis of IBD and suggested as a potential biomarker. Therefore, we aimed to comprehensively analyse the selectivity of PAI-1 in IBD, its correlation with disease activity, and its potential to predict therapeutic response. Methods: Blood, colon biopsy, organoid cultures [OC], and faecal samples were used from active and inactive IBD patients and control subjects. Serpin E1 gene expressions and PAI-1 protein levels and localisation in serum, biopsy, and faecal samples were evaluated by qRT-PCR, ELISA, and immunostaining, respectively. Results: The study population comprised 132 IBD patients [56 CD and 76 UC] and 40 non-IBD patients. We demonstrated that the serum, mucosal, and faecal PAI-1 concentrations are elevated in IBD patients, showing clinical and endoscopic activity. In responders [decrease of eMayo ≥3 in UC; or SES-CD 50% in CD], the initial PAI-1 level decreased significantly upon successful therapy. OCs derived from active IBD patients produced higher concentrations of PAI-1 than the controls, suggesting that epithelial cells could be a source of PAI-1. Moreover, faecal PAI-1 selectively increases in active IBD but not in other organic gastrointestinal diseases. Conclusions: The serum, mucosal, and faecal PAI-1 concentration correlates with disease activity and therapeutic response in IBD, suggesting that PAI-1 could be used as a novel, non-invasive, disease-specific, faecal biomarker in patient follow-up.

9 October 2018 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
ABAnita Bálint
Anita Bálint
MRMariann Rutka
Mariann Rutka
MKMartin Kolar
Martin Kolar
MBMartin Bortlik
Martin Bortlik
DDDana Duricova
Dana Duricova
KFKlaudia Farkas
Klaudia Farkas
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy of CT-P13 therapy in maintaining mucosal healing in UC. Methods: CT-P13 trough levels, antibody positivity, serum inflammatory markers as CRP level, fecal calprotectin at weeks 14 and 54, concomitant steroid and azathioprine therapy at the time of induction therapy and at weeks 14 and 54, previous use of anti TNF drug and the need of dose intensification as possible predictive factors for mucosal healing at week 54 were evaluated in this prospective study. Results: 61 patients had already completed the 54-week treatment period. Mucosal healing was shown in 65.5 % and 62.1 %, complete mucosal healing was present in 31% and 38 % at week 14 and 54, respectively. The median values of CRP, leukocytes, thrombocytes, and albumin showed significant difference between baseline and week 54. Serum antibody positivity was proved in 6.5 % and 19.7 % of cases at week 14 and 54, respectively. Conclusion: Our study confirmed the long-term efficacy of CT-P13 therapy on mucosal healing in UC.